NBIX

#615
Neurocrine Biosciences, Inc. - Common Stock
158.3 0 USD
+1.22%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
158.30
158.30
Range Annuel
1.55
162.39
Changement quotidien
+1.22%
Changement Mensuel
+22.00%
Evolution sur 6 mois
+4.04%
Changement Annuel
+9.17%
Clôture Précédente
156.3 9
Open
158.3 0
Low
158.3 0
High
158.3 0
Volume
309
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26 TTM

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Nouvelles